Analysts Expect Viking Therapeutics Inc (VKTX) to Post -$0.11 EPS

Share on StockTwits

Wall Street analysts expect that Viking Therapeutics Inc (NASDAQ:VKTX) will post earnings per share of ($0.11) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Viking Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.13). Viking Therapeutics posted earnings of ($0.14) per share in the same quarter last year, which suggests a positive year over year growth rate of 21.4%. The company is scheduled to issue its next earnings report on Wednesday, March 6th.

According to Zacks, analysts expect that Viking Therapeutics will report full year earnings of ($0.44) per share for the current financial year, with EPS estimates ranging from ($0.47) to ($0.41). For the next financial year, analysts anticipate that the company will post earnings of ($0.48) per share, with EPS estimates ranging from ($0.55) to ($0.39). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Viking Therapeutics.

Viking Therapeutics (NASDAQ:VKTX) last posted its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.01.

Several research analysts recently commented on VKTX shares. SunTrust Banks started coverage on shares of Viking Therapeutics in a research note on Friday, July 20th. They issued a “buy” rating and a $14.00 target price on the stock. BidaskClub raised shares of Viking Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, July 21st. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Viking Therapeutics in a research note on Friday, August 10th. William Blair reaffirmed an “outperform” rating on shares of Viking Therapeutics in a research note on Friday, August 10th. Finally, Raymond James reaffirmed an “outperform” rating and issued a $43.00 target price (up from $15.00) on shares of Viking Therapeutics in a research note on Tuesday, September 18th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $28.17.

VKTX stock opened at $12.33 on Wednesday. The company has a market cap of $833.44 million, a price-to-earnings ratio of -15.61 and a beta of 2.92. Viking Therapeutics has a one year low of $2.24 and a one year high of $24.00.

In related news, major shareholder Ligand Pharmaceuticals Inc sold 262,881 shares of Viking Therapeutics stock in a transaction on Tuesday, September 25th. The shares were sold at an average price of $19.15, for a total value of $5,034,171.15. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 3.90% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in VKTX. Janney Montgomery Scott LLC bought a new stake in Viking Therapeutics in the second quarter valued at $114,000. Strs Ohio bought a new stake in Viking Therapeutics in the second quarter valued at $120,000. Cubist Systematic Strategies LLC bought a new stake in Viking Therapeutics in the second quarter valued at $129,000. First Mercantile Trust Co. bought a new stake in Viking Therapeutics in the third quarter valued at $131,000. Finally, State Board of Administration of Florida Retirement System bought a new stake in Viking Therapeutics in the second quarter valued at $144,000. Institutional investors and hedge funds own 53.56% of the company’s stock.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.

Recommended Story: How to Invest in an Index Fund

Get a free copy of the Zacks research report on Viking Therapeutics (VKTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply